📣 VC round data is live. Check it out!

iZafe Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for iZafe Group and similar public comparables like Ortivus, Farmaceutica Remedia, Jin Medical International, BPC Instruments and more.

iZafe Group Overview

About iZafe Group

iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.


Founded

2008

HQ

Sweden

Employees

12

Website

izafe.se

Financials (FY)

Revenue: $643K
EBITDA: ($1M)

EV

$17M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

iZafe Group Financials

iZafe Group reported last fiscal year revenue of $643K and negative EBITDA of ($1M).

In the same fiscal year, iZafe Group generated $258K in gross profit, ($1M) in EBITDA losses, and had net loss of ($2M).


iZafe Group P&L

In the most recent fiscal year, iZafe Group reported revenue of $643K and EBITDA of ($1M).

iZafe Group is unprofitable as of last fiscal year, with gross margin of 40%, EBITDA margin of (188%), and net margin of (278%).

See analyst estimates for iZafe Group
Last FY202320242025202620272028
Revenue$643K$196K$854K$643K
Gross Profit$258K$31K($176K)$258K
Gross Margin40%16%(21%)40%
EBITDA($1M)($1M)($2M)($1M)
EBITDA Margin(188%)(686%)(194%)(188%)
EBIT Margin(307%)(2042%)(262%)(307%)
Net Profit($2M)($3M)($2M)($2M)
Net Margin(278%)(1766%)(258%)(278%)

Financial data powered by Morningstar, Inc.

iZafe Group Stock Performance

iZafe Group has current market cap of $17M, and enterprise value of $17M.

Market Cap Evolution


iZafe Group's stock price is $0.04.

iZafe Group share price increased by 5.8% in the last 30 days, and by 60.6% in the last year.

See more trading valuation data for iZafe Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$17M$17M1.8%5.8%-10.7%60.6%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

iZafe Group Valuation Multiples

iZafe Group trades at 26.9x EV/Revenue multiple, and (14.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for iZafe Group

iZafe Group Financial Valuation Multiples

As of May 26, 2026, iZafe Group has market cap of $17M and EV of $17M.

iZafe Group has a P/E ratio of (9.8x).

Last FY202320242025202620272028
EV/Revenue26.9x88.3x20.2x26.9x
EV/EBITDA(14.3x)(12.9x)(10.4x)(14.3x)
EV/EBIT(8.8x)(4.3x)(7.7x)(8.8x)
EV/Gross Profit67.0xn/m(98.5x)67.0x
P/E(9.8x)(5.1x)(7.9x)(9.8x)
EV/FCF(10.6x)(12.7x)(12.7x)(10.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified iZafe Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

iZafe Group Margins & Growth Rates

In the most recent fiscal year, iZafe Group reported gross margin of 40%, EBITDA margin of (188%), and net margin of (278%).

See estimated margins and future growth rates for iZafe Group

iZafe Group Margins

Last FY20242025202720282029
Gross Margin40%(21%)40%
EBITDA Margin(188%)(194%)(188%)
EBIT Margin(307%)(262%)(307%)
Net Margin(278%)(258%)(278%)
FCF Margin(254%)(160%)(254%)

iZafe Group Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth337%(25%)
Gross Profit Growth(658%)(247%)
EBITDA Growth24%(27%)
EBIT Growth(44%)(12%)
Net Profit Growth(36%)(19%)
FCF Growth0%20%

Data powered by FactSet, Inc. and Morningstar, Inc.

iZafe Group Operational KPIs

iZafe Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for iZafe Group
Last FY202320242025202620272028
Revenue per Employee$0.1M
Opex per Employee$0.2M
Opex to Revenue347%2058%242%347%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

iZafe Group Competitors

iZafe Group competitors include Ortivus, Farmaceutica Remedia, Jin Medical International, BPC Instruments, Balsm Alofoq, Prolight Diagnostics, Etropal, Airway Medix, BioRegenx and Cuprina Holdings (Cayman).

Most iZafe Group public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ortivus2.4x(12.2x)
Farmaceutica Remedia0.0x1.0x
Jin Medical International0.4x8.2x
BPC Instruments1.7x7.7x
Balsm Alofoq2.3x12.6x
Prolight Diagnostics(4.4x)
Etropal1.4x17.9x
Airway Medix11589.3x13.3x

This data is available for Pro users. Sign up to see all iZafe Group competitors and their valuation data.

Start Free Trial

iZafe Group M&A Activity

iZafe Group has acquired 2 companies to date.

Last acquisition by iZafe Group was on September 30th 2025. iZafe Group acquired Dosell for $2M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by iZafe Group

Dosell
Pilloxa
Description
Dosell AB is a Swedish medtech company manufacturing automated medication dispensing robots for home care and nursing facilities. Its patented Dosell One device sorts up to 400 daily doses into labeled bags, syncing with electronic health records for timed release via app control. Headquartered in Stockholm, it partners with municipalities and pharmacies across Scandinavia for elderly patient support.
Pilloxa is a Stockholm-based digital health company founded in 2015 that produces a smart pillbox with embedded sensors linked to a mobile app for medication adherence. Developed through collaborations with Royal Institute of Technology, Karolinska Institute, and Stockholm County Council, the device tracks intake and addresses non-compliance issues observed in clinical settings. The product launched commercially post-2017 finalization, targeting patients with complex regimens.
HQ CountrySwedenSweden
HQ City
Stockholm
Stockholm
Deal Date30 Sep 202518 Aug 2022
Valuation$2M$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all iZafe Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About iZafe Group

When was iZafe Group founded?iZafe Group was founded in 2008.
Where is iZafe Group headquartered?iZafe Group is headquartered in Sweden.
How many employees does iZafe Group have?As of today, iZafe Group has over 12 employees.
Is iZafe Group publicly listed?Yes, iZafe Group is a public company listed on Nasdaq Stockholm.
What is the stock symbol of iZafe Group?iZafe Group trades under IZAFE B ticker.
When did iZafe Group go public?iZafe Group went public in 2011.
Who are competitors of iZafe Group?iZafe Group main competitors include Ortivus, Farmaceutica Remedia, Jin Medical International, BPC Instruments, Balsm Alofoq, Prolight Diagnostics, Etropal, Airway Medix, BioRegenx, Cuprina Holdings (Cayman).
What is the current market cap of iZafe Group?iZafe Group's current market cap is $17M.
What is the current revenue of iZafe Group?iZafe Group's last fiscal year revenue is $643K.
What is the current EV/Revenue multiple of iZafe Group?Current revenue multiple of iZafe Group is 26.9x.
Is iZafe Group profitable?No, iZafe Group is not profitable.
How many companies iZafe Group has acquired to date?As of May 2026, iZafe Group has acquired 2 companies.
What was the largest acquisition by iZafe Group?$3M acquisition of Pilloxa on 18th August 2022 was the largest M&A iZafe Group has done to date.
What companies iZafe Group acquired?iZafe Group acquired Pilloxa and Dosell.
In how many companies iZafe Group has invested to date?iZafe Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to iZafe Group

Lists including iZafe Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial